Expert consensus on the medication catalog for drug-induced liver injury and rational drug use
- VernacularTitle:肝损伤药物目录及合理用药专家共识
- Author:
Jianchun LI
1
;
Di CHEN
2
;
Pengfei JIN
2
;
Gerontology NATIONAL
2
;
Association GERIATRIC
2
;
Research PHARMACY
2
;
Society PHARMACY
2
;
Association GERIATRIC
2
Author Information
1. Dept. of Pharmacy，Beijing Hospital/National Center of Gerontology/Institute of Geriatric Medicine，Chinese Academy of Medical Sciences/Beijing Key Laboratory of Assessment of Clinical Drugs Risk and Individual Application （Beijing Hospital），Beijing 100730，China;Dept. of Pharmacy，Aerospace Center Hospital，Beijing 100049，China
2. Dept. of Pharmacy，Beijing Hospital/National Center of Gerontology/Institute of Geriatric Medicine，Chinese Academy of Medical Sciences/Beijing Key Laboratory of Assessment of Clinical Drugs Risk and Individual Application （Beijing Hospital），Beijing 100730，China
- Publication Type:Journal Article
- Keywords:
liver injury;
rational drug use;
hospital pharmacy;
expert consensus
- From:
China Pharmacy
2026;37(3):273-280
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To systematically sort out the drugs causing drug-induced liver injury （DILI） and their relevant information， and to develop the Expert consensus on the medication catalog for drug-induced liver injury and rational drug use （hereinafter referred to as the Consensus）， so as to provide a reference for rational clinical use. METHODS Systematic searches were conducted across various literature databases， guideline retrieval websites and professional liver injury websites. Drugs identified as causing DILI from the included literature and online resources were extracted and assigned scores based on source credibility： three points for LiverTox A-class drugs and two points for B-class drugs； two points for drugs from Hepatox and guidelines； and one point for drugs from consensus and related literature sources. Drugs classified as LiverTox category A/B or with total scores ≥4 were included in the preliminary list of DILI-causing drugs. Opinions were collected and integrated from a multidisciplinary expert panel comprising 45 medical and pharmaceutical experts from 27 provinces across China through three rounds of the Delphi method （including questionnaires and discussion sessions）， and after revision， the final version of Consensus was formed. RESULTS & CONCLUSIONS This Consensus included 12 traditional Chinese medicines （TCMs） such as Polygoni Multiflori Radix and Ephedrae Herba， 151 Western medicines including amiodarone and atorvastatin， along with rational use information. For TCM， eight rational use information were included： evidence-based score， liver injury classification based on pathogenesis， liver injury classification based on biochemical abnormality pattern， clinical phenotype， laboratory examination manifestations， latency period， recovery time， and management strategies. For Western medicines， six additional items were included based on the TCM， namely liver function monitoring， discontinuation， contraindications， cautions， dose adjustments， and risk factors， totaling 14 items. This Consensus systematically compiles DILI drugs and their rational use information， which will support clinicians in enhancing the prevention， identification， and management of DILI， reducing the incidence of liver injury， and ensuring patient medication safety and efficacy.
